Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer

(2011) Roisin M. Connolly et al.   BREAST CANCER RESEARCH AND TREATMENT

Population pharmacokinetic analysis of sorafenib in patients with solid tumours

(2011) Lokesh Jain et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group

(2011) G. Lainakis et al.   CLINICAL NEPHROLOGY

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

(2011) K Eechoute et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic Impact of SLCO1A2 Polymorphisms on Imatinib Disposition in Patients With Chronic Myeloid Leukemia

(2011) Y Yamakawa et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours

(2011) M.J.A. de Jonge et al.   EUROPEAN JOURNAL OF CANCER

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis

(2011) R.A. Hilger et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Clinical Results and Pharmacokinetics of Sorafenib in Chronic Hemodialysis Patients with Metastatic Renal Cell Carcinoma in a Single Center

(2011) T. Kennoki et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium

(2011) Richard Aplenc et al.   JOURNAL OF CLINICAL ONCOLOGY

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

(2011) Sang Kyun Sohn et al.   LEUKEMIA & LYMPHOMA

Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group

(2011) Martin A. Champagne et al.   PEDIATRIC BLOOD & CANCER

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase

(2011) Naoto Takahashi et al.   PHARMACOLOGY

Pharmacokinetics and Pharmacodynamics of Nilotinib in Gastrointestinal Stromal Tumors

(2011) Jonathan Trent et al.   SEMINARS IN ONCOLOGY

Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma

(2010) Robert J. Motzer et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Imatinib and Panax Ginseng: A Potential Interaction Resulting in Liver Toxicity

(2010) Naveen Bilgi et al.   ANNALS OF PHARMACOTHERAPY

Dasatinib

(2010) Fabrizio Condorelli et al.   BIODRUGS

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

(2010) H. Wildiers et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

(2010) I M E Desar et al.   BRITISH JOURNAL OF CANCER

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

(2010) E Boven et al.   BRITISH JOURNAL OF CANCER

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

(2010) C-F Xu et al.   BRITISH JOURNAL OF CANCER

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

(2010) P Hamberg et al.   BRITISH JOURNAL OF CANCER

Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia

(2010) Dong-Wook Kim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes

(2010) Noelia Nebot et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

(2010) Faye M. Johnson et al.   CANCER

The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1

(2010) Ken-ichi Fujita et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

(2010) Carlo L. Bello et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

(2010) Erich Brendel et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid

(2010) Werner J. Heinz et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Marginal increase of sunitinib exposure by grapefruit juice

(2010) Nielka P. van Erp et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?

(2010) Margaret von Mehren et al.   CANCER TREATMENT REVIEWS

Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma

(2010) Silvia Park et al.   CHEMOTHERAPY

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

(2010) U. N. Vaishampayan et al.   CLINICAL CANCER RESEARCH

Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib

(2010) A. A. M. van der Veldt et al.   CLINICAL CANCER RESEARCH

Effects of Nilotinib on Single-Dose Warfarin Pharmacokinetics and Pharmacodynamics

(2010) Ophelia Q.P. Yin et al.   CLINICAL DRUG INVESTIGATION

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

(2010) B C Goh et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers

(2010) A Lindauer et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors

(2010) E I Heath et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study

(2010) Ophelia Q.P. Yin et al.   CLINICAL THERAPEUTICS

CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity

(2010) Henrik Gréen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development

(2010) Marie-Paule Sablin et al.   Expert Opinion on Drug Metabolism & Toxicology

Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study

(2010) Keiko Shinsako et al.   International Journal of Clinical Oncology

A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors

(2010) Christopher J. Sweeney et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib

(2010) Ophelia Q. P. Yin et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants

(2010) Chiaki Tanaka et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

(2010) Naoto Takahashi et al.   JOURNAL OF HUMAN GENETICS

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

(2010) F J Giles et al.   LEUKEMIA

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review

(2010) Xin An et al.   LEUKEMIA RESEARCH

Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study

(2010) Martin Reck et al.   LUNG CANCER

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

(2010) J Rafael Sierra et al.   Molecular Cancer

Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort

(2010) M. Quintela-Fandino et al.   MOLECULAR CANCER THERAPEUTICS

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

(2010) J. S. Lagas et al.   MOLECULAR CANCER THERAPEUTICS

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

(2010) F. M. Iwamoto et al.   NEURO-ONCOLOGY

Dasatinib, a Multikinase Inhibitor: Therapy, Safety, and Appropriate Management of Adverse Events

(2010) Sepideh Shayani   THERAPEUTIC DRUG MONITORING

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib

(2010) Lance Cowey   OncoTargets and Therapy

Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors

(2010) Susan A. J. Vaziri et al.   Current Oncology Reports

Tyrosine Kinase Inhibitors: The First Decade

(2010) Meetu Agrawal et al.   Current Hematologic Malignancy Reports

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

(2009) Kristy J. Gotink et al.   ANGIOGENESIS

Pharmacokinetics of sunitinib in an obese patient with a GIST

(2009) I. M. E. Desar et al.   ANNALS OF ONCOLOGY

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

(2009) M. Kozloff et al.   ANNALS OF ONCOLOGY

Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib

(2009) Kyoichi Takahashi   ARCHIVES OF OPHTHALMOLOGY

Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

(2009) Amit K. Tiwari et al.   BIOCHEMICAL PHARMACOLOGY

Dasatinib

(2009) Susan J Keam   BIODRUGS

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

(2009) J. L. Snead et al.   BLOOD

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib

(2009) Merrill J. Egorin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

(2009) Joshua Ö. Haznedar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

(2009) Francisco Robert et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

(2009) George Fountzilas et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib

(2009) Judith Meza-Junco et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters

(2009) S. Hu et al.   CLINICAL CANCER RESEARCH

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

(2009) B. E. Houk et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

(2009) C Tanaka et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: A single- and multiple-dose, open-label pharmacokinetic study in Chinese patients

(2009) Li Zhou et al.   CLINICAL THERAPEUTICS

Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2

(2009) Shu-Feng Zhou et al.   DRUG METABOLISM REVIEWS

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

(2009) S. George et al.   EUROPEAN JOURNAL OF CANCER

Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia

(2009) Dong-Wook Kim et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL

(2009) Arinobu Tojo et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

(2009) Kuniaki Shirao et al.   INVESTIGATIONAL NEW DRUGS

New HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma

(2009) Silvia De Francia et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

A high-performance liquid chromatography–mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum

(2009) Robert A. Parise et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma

(2009) Marie-Christine Etienne-Grimaldi et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Development of a high-performance liquid chromatographic–mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib

(2009) Sandra Roche et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry

(2009) A. Haouala et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

(2009) Antonius A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

(2009) Nielka P. van Erp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects

(2009) Timothy Eley et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants

(2009) Ophelia Q. P. Yin et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

(2009) Reza Khosravan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

(2009) B. Blanchet et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

(2009) Peter de Bruijn et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib

(2009) Y. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

(2009) Elias Jabbour et al.   MAYO CLINIC PROCEEDINGS

Lack of Association Between Excretion of Sorafenib in Sweat and Hand-Foot Skin Reaction

(2009) Lokesh Jain et al.   PHARMACOTHERAPY

Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)

(2009) Tong Shen et al.   PLoS One

Pharmacokinetics of sunitinib in hemodialysis

(2008) H. Izzedine et al.   ANNALS OF ONCOLOGY

Imatinib use during pregnancy and breast feeding: a case report and review of the literature

(2008) Ridvan Ali et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1

(2008) Bertrand Rochat et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

(2008) S. Dulucq et al.   BLOOD

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

(2008) K. Porkka et al.   BLOOD

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia

(2008) Yanfeng Wang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of antacid on imatinib absorption

(2008) Brian A. Sparano et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

(2008) Divya Menon-Andersen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Imatinib for hepatocellular cancer – Focus on pharmacokinetic/pharmacodynamic modelling and liver function

(2008) G. Treiber et al.   CANCER LETTERS

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

(2008) Hironobu Minami et al.   CANCER SCIENCE

Nilotinib

(2008) M. W. Deininger   CLINICAL CANCER RESEARCH

Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC

(2008) N. van Erp et al.   CLINICAL CANCER RESEARCH

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

(2008) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Interaction of Imatinib with Human Organic Ion Carriers

(2008) S. Hu et al.   CLINICAL CANCER RESEARCH

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

(2008) D. K. Hiwase et al.   CLINICAL CANCER RESEARCH

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

(2008) M. Hazarika et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults

(2008) A. Petain et al.   CLINICAL CANCER RESEARCH

Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

(2008) David L. DeRemer et al.   CLINICAL THERAPEUTICS

Targeted Drugs in Chronic Myeloid Leukemia

(2008) Joanna Gora-Tybor et al.   CURRENT MEDICINAL CHEMISTRY

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials

(2008) Shreyaskumar Patel et al.   EUROPEAN JOURNAL OF CANCER

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

(2008) O. A. Cornely et al.   HAEMATOLOGICA

Quantification of sunitinib in human plasma by high-performance liquid chromatography–tandem mass spectrometry☆

(2008) P MINKIN et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Inhibition of Imatinib Transport by Uremic Toxins During Renal Failure

(2008) Ryan M. Franke et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib for Patients With Liver or Kidney Dysfunction: No Need to Modify the Dose

(2008) Ian R. Judson   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

(2008) Joseph Gibbons et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

(2008) Ramesh K. Ramanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography–mass spectrometry

(2008) Bertrand Rochat et al.   JOURNAL OF MASS SPECTROMETRY

Effect of Hemodialysis on Hepatic Cytochrome P450 Functional Expression

(2008) Josée Michaud et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma

(2008) David A. Reardon et al.   NEURO-ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenomic importance of ABCG2

(2008) George Cusatis et al.   PHARMACOGENOMICS

Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasma

(2007) Lokesh Jain et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS